For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Cardiogen (Ala-Glu-Asp-Arg, AEDR) is a synthetic tetrapeptide derived from cardiac tissue protein analysis, developed by Professor Khavinson's group as the heart-targeted member of the Khavinson bioregulator family. Its published evidence base is entirely preclinical: cell culture studies showing 2 to 5 times upregulation of cytoskeletal proteins and reduced apoptosis markers in fibroblasts, a coronary ligation mouse model reporting threefold mortality reduction, and a rat sarcoma model showing dose-dependent tumor inhibition via vascular disruption. No completed human clinical trials have been published. Unlike Vesugen, which has Russian observational data in cardiovascular patients, Cardiogen has no human clinical data of any kind in indexed literature.
Cardiogen is a research compound with no FDA or EMA approval and no completed human clinical trials, controlled or uncontrolled, for any indication. Unlike Vesugen (which has observational Russian clinical data in cardiovascular patients) or Epithalon (which has Russian observational data in elderly cohorts), Cardiogen has no published human clinical data of any kind in indexed literature as of March 2026. The entire evidence base is animal and in vitro.
Commercial vendor materials and the St. Petersburg Institute's own product pages describe Cardiogen as suitable for treating coronary heart disease, hypertension, heart failure, angina, and myocardial hypertrophy. These are serious cardiovascular conditions that require evidence-based medical treatment. Using a preclinical-only compound as a substitute for or adjunct to guideline-directed medical therapy for these conditions is not supported by any published clinical evidence.
A naming disambiguation is important: there is no relationship between the Khavinson peptide Cardiogen (AEDR) and the Szeged CardioGen Registry in Hungary (a clinical database for cardiomyopathy and ion channel diseases) or the CardioGen genomic interpretation system from BGI Genomics in China. These are entirely unrelated products sharing a similar name.
The entire Cardiogen research base originates from the St. Petersburg Institute of Bioregulation and Gerontology, with Professor Khavinson and colleagues as authors across virtually all primary publications. No independent replication by external institutions has been identified in indexed literature.
Cardiogen (also designated T-30 or AKS-K in some commercial preparations) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Arg (AEDR), developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It is the cardiac-targeted member of the Khavinson bioregulator family, alongside the vascular-targeted Vesugen (Lys-Glu-Asp), the pineal-targeted Epithalon (Ala-Glu-Asp-Gly), and the cerebral-targeted Cortagen (Ala-Glu-Asp-Pro).
The design methodology was the same applied across the Khavinson family: quantitative amino acid analysis of peptide extracts from bovine cardiac tissue identified alanine, glutamic acid, aspartic acid, and arginine as the most abundant short-chain components. The AEDR tetrapeptide was synthesized as a candidate active fraction of the native cardiac peptide pool. The hypothesis is that cardiac tissue produces regulatory peptides that decline with age and disease, and that exogenous AEDR supplementation can restore protein synthesis and reduce apoptosis in cardiac cells.
The vascular endothelium and cardiac fibroblasts are identified in the literature as Cardiogen's principal cellular targets, with secondary effects proposed in cardiomyocytes. Cardiac fibroblasts, which constitute approximately 60 to 70 percent of non-myocyte cells in the heart, play critical roles in tissue repair, collagen deposition, and remodeling after injury. Excessive fibroblast activation leads to cardiac fibrosis, the pathological stiffening and scarring of myocardium that drives heart failure progression. The theoretical case for Cardiogen is that it promotes cardiomyocyte proliferation while modulating fibroblast activity to reduce fibrotic remodeling.
Note on naming: the commercial supplement product sold by the St. Petersburg Institute contains a preparation designated "peptide complex AKS-K" composed of linked amino acids including those of the AEDR sequence. This is functionally described as Cardiogen but may differ from the pure synthetic AEDR tetrapeptide used in research studies. The relationship between the supplement preparation and the research compound is not formally characterized in indexed literature.
Cardiogen's proposed primary mechanism is upregulation of cytoskeletal and nuclear matrix protein synthesis in cardiac cells, leading to increased cell proliferation and reduced apoptosis. This was characterized most directly in the 2012 Khavinson et al. paper published in Bulletin of Experimental Biology and Medicine, which used cultured mouse embryonic fibroblasts lacking the LMNA gene (lamin A/C knockout cells) as a model system.
In that study, fibroblasts were exposed to Cardiogen for 30 minutes. Compared to untreated controls, Cardiogen-treated cells showed 2 to 5 times higher expression of the cytoskeletal proteins actin, tubulin, and vimentin, and 2 to 3 times higher expression of the nuclear matrix proteins lamin A and lamin C. The authors concluded that Cardiogen's cardioprotective activity is determined by its capacity to activate synthesis of cytoskeletal and nuclear matrix proteins, which stimulates cell proliferation and reduces apoptosis.
Lamin A and C are structural proteins of the nuclear lamina, the meshwork beneath the nuclear envelope that governs nuclear shape, chromatin organization, and gene expression. Mutations in the LMNA gene cause laminopathies, including several forms of cardiomyopathy and muscular dystrophy. The fact that Cardiogen restores lamin A/C expression in lamin-deficient cells is mechanistically interesting, though the relevance to hearts with intact LMNA genes is less clear.
A second mechanistic element is p53 suppression. Multiple secondary sources and some primary reports indicate that Cardiogen reduces p53 protein expression in cardiac tissue models. p53, often called the guardian of the genome, is a potent inducer of apoptosis when cells are damaged. Its suppression by Cardiogen would reduce programmed cell death in cardiomyocytes exposed to ischemic or mechanical stress. The papers cited for the myocardial infarction model findings support this interpretation, though effect sizes and experimental details are not fully accessible in translation.
Cell penetration has been documented separately by Fedoreyeva et al. (2011, Biochemistry/Biokhimiia), who tracked fluorescein isothiocyanate-labeled short peptides including AEDR in HeLa cells, demonstrating nuclear entry and in vitro interaction with double-stranded DNA and deoxyribooligonucleotides. Cardiogen showed selective quenching of fluorescence in DNA-ethidium bromide complexes, indicating binding to double-stranded DNA. Binding was not observed with single-stranded DNA, consistent with a minor groove interaction pattern proposed for other Khavinson bioregulators.
The proposed epigenetic mechanism follows the same logic as for Epithalon, Vilon, and Cortagen: charged peptide residues dock in the DNA minor groove, displacing or repositioning nucleosomal proteins at promoter regions, thereby increasing transcription factor access to genes encoding structural and repair proteins. For Cardiogen, the AEDR sequence with its acidic (Glu, Asp) and basic (Arg) residues provides the charge complementarity for this interaction. This mechanism is plausible and consistent with the protein upregulation data, but it is inferred from the cell culture and docking studies rather than directly demonstrated in cardiac tissue in vivo.
In an experimental mouse model of myocardial injury created by coronary artery ligation, administration of the AEDR tetrapeptide reportedly produced a threefold reduction in mortality compared to the control group. Necrotic zones in myocardial tissue were reportedly reduced. Myocardial glycogen content was better preserved in treated animals, suggesting that treated cells maintained energy storage capacity. Mitochondrial protective effects were also described.
The reduction in p53 protein expression proposed as a mechanism is consistent with reduced cardiomyocyte apoptosis following ischemic insult, which is a well-established driver of infarct expansion and post-MI remodeling.
Important caveat: the primary source for the threefold mortality reduction claim is not independently identified in indexed PubMed-searchable literature. The finding is described in secondary sources and in the St. Petersburg Institute's own materials, but the specific primary publication, journal, volume, and year cannot be confirmed through available indexed databases. This does not mean the study does not exist, as Russian-language publications frequently appear in non-indexed journals or translation journals with inconsistent indexing. However, it cannot be verified independently.
The threefold mortality reduction in a coronary ligation model, if real, would be a substantial finding in a clinically relevant model. The mechanism proposed (p53 suppression reducing cardiomyocyte apoptosis, glycogen preservation, mitochondrial protection) is internally coherent. The inability to independently locate the primary publication limits confidence. This remains the most compelling claimed finding for Cardiogen and the most important target for independent replication.
The 2012 Khavinson et al. study is the most direct mechanistic publication for Cardiogen in indexed literature. In mouse embryonic fibroblasts from LMNA knockout mice, 30-minute exposure to AEDR produced 2 to 5 times higher expression of cytoskeletal proteins (actin, tubulin, vimentin) and 2 to 3 times higher expression of nuclear matrix proteins (lamin A, lamin C) compared to untreated controls. The authors stated this explains Cardiogen's cardioprotective activity through stimulation of cell proliferation and reduction of apoptosis.
The Fedoreyeva 2011 study established that short fluorescence-labeled peptides including AEDR enter HeLa cell nuclei and interact with double-stranded DNA in vitro. AEDR showed selective quenching of fluorescence in methylated and unmethylated lambda phage DNA-ethidium bromide complexes but did not bind single-stranded DNA, consistent with double-stranded DNA minor groove targeting. This provides the mechanistic basis for proposed epigenetic gene regulation.
The use of LMNA knockout fibroblasts is a noteworthy model choice: these cells are deficient in lamin A and C and thus particularly sensitive to lamin-restoring interventions. The magnitude of the response in this pathological model may not represent the effect in normal cardiac cells with intact lamins.
The 2012 protein upregulation study is the most rigorously reported piece of primary Cardiogen research in indexed English-language literature. The cell biology findings are clear and the model is well characterized. The limitation is that LMNA knockout fibroblasts are not normal cardiac cells, and the 2 to 5 fold protein upregulation in this deficient model does not predict effect size in normal or ischemic cardiac tissue. The nuclear entry and DNA interaction data from Fedoreyeva 2011 provide mechanistic support for epigenetic gene regulation but were conducted in HeLa (cervical cancer) cells rather than cardiac cells.
The 2009 Chalisova et al. study used organotypic myocardial tissue culture from young and old rats, a model that preserves cell-cell contacts better than dissociated cell culture. The study stated that Cardiogen demonstrated great stimulating effect on proliferation both in tissues from young and old rats, with the effect described as quantitatively notable. The peptide outperformed individual amino acid controls in promoting proliferative activity, suggesting that the intact tetrapeptide sequence rather than its amino acid constituents drives the biological effect.
The tissue culture model tested Cardiogen against the amino acids that compose it to address whether the observed effects could be attributed to nutritional amino acid availability rather than peptide-specific signaling. The finding that the intact AEDR sequence exceeded the individual amino acid effects supports a sequence-specific mechanism.
Full quantitative data from this study are not available in accessible translated text. The study is indexed on PubMed with PMID 20210190 but the full text is in Russian.
This study addresses a methodologically important question: does the intact tetrapeptide sequence matter, or are the effects merely from amino acid availability? The finding that the intact sequence outperformed individual amino acids is supportive of a sequence-specific peptide mechanism. The limitation is the organotypic culture model, which is ex vivo heart tissue and does not recapitulate the in vivo cardiac environment. Quantitative data are unavailable from indexed English sources.
In aged rats with transplanted M-1 sarcoma, Cardiogen injection at multiple doses produced dose-dependent inhibition of tumor growth. The level of apoptosis in tumor cells was higher in all Cardiogen-treated groups compared to controls. Growth inhibition was caused by the development of hemorrhagic necrosis within tumor tissue and stimulation of tumor cell apoptosis.
Proliferative activity parameters indicated that inhibition of tumor growth was not caused by a direct cytostatic effect on tumor cells, ruling out a chemotherapy-type mechanism. Morphological signs pointed to a specific mechanism realized through the vascular network of the tumor, suggesting Cardiogen disrupted tumor neovascularization rather than directly killing tumor cells.
This finding is mechanistically interesting because it is the opposite of Cardiogen's proposed cardiac effect: in cardiac cells, Cardiogen is said to reduce apoptosis, whereas in sarcoma cells, it promotes apoptosis. The authors proposed that this reflects context-dependent activity: in normal stressed cardiac tissue, Cardiogen supports cell survival; in malignant tissue, it promotes death through vascular disruption. The mechanism through the tumor vascular network would connect this to Cardiogen's putative effects on vascular endothelial cells, shared with Vesugen.
This is the only Cardiogen publication from the St. Petersburg Institute that is fully indexed and publicly cited with clear study parameters.
The M-1 sarcoma data are the most thoroughly documented Cardiogen findings in the indexed literature. The vascular disruption mechanism is coherent with the broader biology and connects to Cardiogen's proposed endothelial effects. The context-dependent apoptosis effects (pro-survival in cardiac, pro-death in tumor) are biologically plausible but require systematic investigation to understand the molecular switch. This is preclinical animal data from one institution in a model that does not represent any common human cancer type.
In aging human prostate fibroblast cultures, Cardiogen and several similarly structured peptides modulated the expression of signaling factors associated with fibroblast differentiation. In senescent fibroblasts, these signaling factors showed altered expression patterns consistent with the stromal microenvironment changes that correlate with prostate cancer development and progression. Cardiogen treatment reportedly reduced these age-altered signaling factor levels toward patterns characteristic of younger fibroblast cultures.
The authors proposed that this normalizing effect on prostate stromal fibroblast signaling could reduce the pro-tumorigenic microenvironment that forms with aging, potentially relevant to prostate cancer risk.
The study represents the only published evidence connecting Cardiogen to prostate tissue biology. The model is human-derived (prostate fibroblast cultures from donors of different ages), making it more proximal to clinical relevance than rodent models. However, in vitro cell culture of stromal fibroblasts is several steps removed from clinical prostate cancer biology. The primary publication is in Russian with no full-text English translation available.
An unexpected finding given Cardiogen's nominal cardiac focus. The mechanism makes sense given that Cardiogen's primary cellular target is fibroblasts broadly, not cardiac fibroblasts specifically. The human prostate fibroblast data point to a more generalized anti-aging fibroblast signaling effect that could, in principle, operate in multiple tissue contexts. The evidence is preliminary and from a Russian-language publication. It does not establish any clinical utility in prostate disease.
Khavinson bioregulator peptide.
No human pharmacokinetic or dose-finding study has been published for Cardiogen. All human dosing protocols are entirely extrapolated from commercial product labeling and vendor convention, not from clinical trials. The doses shown (200 to 1000 mcg daily SubQ) reflect the range of research vendor protocols and have no clinical validation. The commercial oral supplement form contains unlisted concentrations of the AKS-K peptide complex and its bioavailability is not characterized.
Within the Khavinson bioregulator family, Cardiogen has the weakest clinical evidence profile. Epithalon has Russian observational longevity data spanning decades. Vesugen has uncontrolled but published human cardiovascular studies including an n=41 post-surgical series. Vilon has in vitro human lymphocyte data and animal longevity data. Cardiogen has none of these. Mechanistically, Cardiogen shares the same chromatin remodeling framework as the other family members, but the cardiac-fibroblast focus connects it most closely to established biology of post-MI remodeling, where fibrosis suppression and cardiomyocyte preservation are actively pursued drug targets. If the MI mortality data were independently replicated and published, Cardiogen would warrant serious research attention. The field of cardiac regeneration does not lack for interesting preclinical compounds, most of which also fail to translate. Cardiogen's tumor-modifying activity via vascular disruption in the sarcoma model provides an unexpected parallel to the vascular mechanism proposed for Vesugen.
No human pharmacokinetic or safety data have been published for Cardiogen. No human exposure of any kind is documented in indexed literature. The following reflects animal and in vitro observations only.
In the rat sarcoma study (Levdik and Knyazkin, 2009, Bulletin of Experimental Biology and Medicine), injections of Cardiogen across multiple dose groups in aged rats produced no described adverse effects in tumor-free tissues. In the myocardial infarction mouse model, no adverse effects are reported in treated animals beyond the expected consequences of the coronary ligation procedure itself.
The compound is composed entirely of amino acids present in normal human physiology. Tetrapeptides of this size are expected to be rapidly metabolized by peptidases in blood and tissue. No organ toxicity, immunogenic response, or systemic side effects have been reported in any published animal study.
The commercial supplement sold by the St. Petersburg Institute includes inactive ingredients (microcrystalline cellulose, beet root sugar, lactose, starch, Tween-80). Individuals with lactose intolerance or beet sugar sensitivity should be aware of these excipients if considering the oral formulation.
The p53 suppression mechanism warrants contextual caution. p53 is a major tumor suppressor; its sustained downregulation in normal cells would theoretically increase cancer risk. The cell-culture evidence suggests Cardiogen reduces p53 expression in cardiac cells under stress conditions. Whether this effect persists in healthy unstressed tissue at commercial dosing schedules is not characterized. The rat sarcoma study showed Cardiogen induced apoptosis in tumor cells (the opposite of p53 suppression), suggesting the p53 effects may be context-dependent, but this has not been systematically investigated across tissue types.
Cardiogen is the most clinically un-validated member of the Khavinson bioregulator family despite being positioned as the cardiac-targeted compound. Vesugen (vascular), Epithalon (pineal/aging), and even Cortagen (neural) all have either more developed in vitro mechanisms, more extensive animal data, or in the case of Vesugen, some degree of human observational data. Cardiogen's published indexed evidence consists primarily of two cell culture studies (the 2012 cytoskeletal protein paper and the 2011 nuclear entry paper), one rat sarcoma study, and one organotypic cardiac tissue culture paper. The most clinically compelling claim, the threefold mortality reduction in a coronary ligation model, cannot be independently verified from available indexed literature.
The mechanistic case has real scientific substance. A tetrapeptide that enters the nucleus, binds double-stranded DNA specifically, upregulates lamin A/C and cytoskeletal proteins in fibroblasts, and produces context-dependent apoptosis regulation in cardiac versus tumor tissue is describing a genuine and interesting biological activity. The problem is that this activity has been demonstrated in cell lines and tissue culture models using highly artificial conditions (LMNA knockout cells, 30-minute incubation times, xenograft sarcoma) that do not map directly to human cardiovascular disease.
The commercial supplement sold by the St. Petersburg Institute lists Cardiogen as appropriate for treating coronary heart disease, hypertension, heart failure, angina, myocardial hypertrophy, myocarditis, and myocardiodystrophy. These are serious conditions with established guideline-directed treatment protocols. Promoting a preclinical-only compound for these indications, without any published human trial data, is the most significant concern in this profile. Cardiogen represents an interesting research hypothesis that has not been taken to clinical testing, packaged and sold as a therapeutic product for life-threatening cardiac conditions.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use